Results of a controlled trial conducted by Cherry Creek Research, Inc, in Colorado show that using the 3-mg drospirenone/20-µg ethinyl estradiol 24/4 combined oral contraceptive pill (OCP) can reduce acne lesion counts in females in the age group of 14 to 45 years. Modification of androgen (major cause of acne pathogenesis) can be a potential hormonal therapy for acne. Lesions were reduced by 46.3% in the group which received the combination therapy and the participants having “almost clear” skin was about 3 times greater than the placebo group. The study was funded by Bayer Schering Pharma AG.